Reckitt Benckiser Group Plc (LON:RB) insider Laxman Narasimhan sold 14,718 shares of the business’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of GBX 5,833 ($76.73), for a total transaction of £858,500.94 ($1,129,309.31).
Laxman Narasimhan also recently made the following trade(s):
- On Tuesday, March 3rd, Laxman Narasimhan bought 17,241 shares of Reckitt Benckiser Group stock. The stock was purchased at an average price of GBX 5,800 ($76.30) per share, with a total value of £999,978 ($1,315,414.36).
LON RB opened at GBX 5,750 ($75.64) on Friday. The company has a market cap of $40.82 billion and a PE ratio of -11.06. The stock’s 50 day simple moving average is GBX 6,049.70 and its 200-day simple moving average is GBX 6,093.88. Reckitt Benckiser Group Plc has a 1-year low of GBX 5,130 ($67.48) and a 1-year high of GBX 8,191.30 ($107.75). The company has a debt-to-equity ratio of 130.80, a current ratio of 0.56 and a quick ratio of 0.41.
The company also recently announced a dividend, which will be paid on Thursday, May 28th. Stockholders of record on Thursday, April 16th will be given a GBX 101.60 ($1.34) dividend. This represents a dividend yield of 1.64%. The ex-dividend date is Thursday, April 16th. This is an increase from Reckitt Benckiser Group’s previous dividend of $73.00. Reckitt Benckiser Group’s dividend payout ratio (DPR) is -0.39%.
Several research firms recently issued reports on RB. BNP Paribas upgraded shares of Reckitt Benckiser Group to an “outperform” rating and decreased their target price for the company from GBX 6,500 ($85.50) to GBX 6,300 ($82.87) in a research note on Wednesday, March 18th. UBS Group set a GBX 5,700 ($74.98) target price on shares of Reckitt Benckiser Group and gave the company a “neutral” rating in a research note on Tuesday. Royal Bank of Canada boosted their target price on shares of Reckitt Benckiser Group from GBX 5,000 ($65.77) to GBX 5,300 ($69.72) and gave the company an “underperform” rating in a research note on Monday. Barclays reiterated an “overweight” rating on shares of Reckitt Benckiser Group in a research note on Thursday, March 19th. Finally, HSBC decreased their target price on shares of Reckitt Benckiser Group from GBX 7,100 ($93.40) to GBX 6,800 ($89.45) and set a “buy” rating for the company in a research note on Wednesday, March 18th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of GBX 6,386.58 ($84.01).
About Reckitt Benckiser Group
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands.
See Also: Dead Cat Bounce
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.